Wikipedia

IKBKAP

IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein) is a human gene encoding the IKAP protein, which is ubiquitously expressed at varying levels in all tissue types, including brain cells.[1] The IKAP protein is thought to participate as a sub-unit in the assembly of a six-protein putative human holo-Elongator complex,[2] which allows for transcriptional elongation by RNA polymerase II. Further evidence has implicated the IKAP protein as being critical in neuronal development, and directs that decreased expression of IKAP in certain cell types is the molecular basis for the severe, neurodevelopmental disorder familial dysautonomia.[3] Other pathways that have been connected to IKAP protein function in a variety of organisms include tRNA modification,[citation needed] cell motility,[4] and cytosolic stress signalling.[1] Homologs of the IKBKAP gene have been identified in multiple other Eukaryotic model organisms. Notable homologs include Elp1 in yeast,[5] Ikbkap in mice,[6] and D-elp1 in fruit flies. The fruit fly homolog (D-elp1) has RNA-dependent RNA polymerase activity and is involved in RNA interference.[citation needed]

Inhibitor of κ light polypeptide gene enhancer in B-cells, kinase complex-associated protein
Identifiers
SymbolIKBKAP
Alt. symbolsFD, DYS, ELP1, IKAP, IKI3, TOT1, FLJ12497 and DKFZp781H1425
NCBI gene8518
HGNC5959
OMIM603722
RefSeqNM_003640
UniProtO95163
Other data
LocusChr. 9 q13
Search for
StructuresSwiss-model
DomainsInterPro

The IKBKAP gene is located on the long (q) arm of chromosome 9 at position 31, from base pair 108,709,355 to base pair 108,775,950.

Function and mechanism

edit

Originally, it was proposed that the IKBKAP gene in humans was encoding a scaffolding protein (IKAP) for the IκB enzyme kinase (IKK) complex, which is involved in pro-inflammatory cytokine signal transduction in the NF-κB signalling pathway.[7] However, this was subsequently disproven when researchers applied a gel filtration method and could not identify IKK complexes contained in fractions with IKAP, thus dissociating IKAP from having a role in the NF-κB signalling pathway.[8]

 
Dimerization of Elp1 is essential for Elongator complex assembly.

Later, it was discovered that IKAP functions as a cytoplasmic scaffold protein in the mammalian JNK-signalling pathway which is activated in response to stress stimuli. In an in vivo experiment, researchers showed direct interaction between IKAP and JNK induced by the application of stressors such as ultraviolet light and TNF-α (a pro-inflammatory cytokine).[1]

IKAP is now also widely acknowledged to have a role in transcriptional elongation in humans. The RNA polymerase II holoenzyme constitutes partly of a multi-subunit histone acetyltransferase element known as the RNA polymerase II elongator complex, of which IKAP is one subunit.[9] The association of the elongator complex with RNA polymerase II holoenzyme is necessary for subsequent binding to nascent pre-mRNA of certain target genes, and thus their successful transcription.[10] Specifically, within the cell, the depletion of functional elongater complexes due to low IKAP expression has been found to have a profound effect on transcription of genes involved in cell migration.[11]

In yeast, experimental data shows the elongator complex functioning in a variety of processes — from exocytosis to tRNA modification.[12] This finding demonstrates that the function of the elongator complex is not conserved among species.

edit

Familial Dysautonomia

edit

Familial dysautonomia (also known as “Riley-Day syndrome”) is a complex congenital neurodevelopmental disease, characterized by unusually low numbers of neurons in the sensory and autonomic nervous systems. The resulting symptoms of patients include gastrointestinal dysfunction, scoliosis, and pain insensitivity. This disease is especially prevalent in the Ashkenazi Jewish population, where 1/3600 live births present familial dysautonomia.[3]

By 2001, the genetic cause of familial dysautonomia was localized to a dysfunctional region spanning 177kb on chromosome 9q31. With the use of blood samples from diagnosed patients, the implicated region was successfully sequenced. The IKBKAP gene, one of the five genes identified in that region, was found to have a single-base mutation in over 99.5% of cases of familial dysautonomia seen.[3]

The single-base mutation, overwhelmingly noted as a transition from cytosine to thymine, is present in the 5’ splice donor site of intron 20 in the IKBKAP pre-mRNA. This prevents recruitment of splicing machinery, and thus exon 19 is spliced directly to exon 21 in the final mRNA product – exon 20 is removed from the pre-mRNA with the introns. The unintentional removal of an exon from the final mRNA product is termed exon skipping.[3] Therefore, there is a decreased level of functional IKAP protein expression within affected tissue. However, this disorder is tissue-specific. Lymphoblasts, even with the mutation present, may continue to express some functional IKAP protein. In contrast, brain tissue with the single-base mutation in the IKBKAP gene predominantly express a resulting truncated, mutant IKAP protein which is nonfunctional.[3] The exact mechanism for how the familial dysautonomia phenotype is induced due to reduced IKAP expression is unclear; still, as a protein involved in transcriptional regulation, there have been a variety of proposed mechanisms. One such theory suggests that critical genes in the development of wild-type sensory and autonomic neurons are improperly transcribed.[3] An extension of this research suggests that genes involved in cell migration are impaired in the nervous system, creating a foundation for this disorder.[4]

In a small number of reported familial dysautonomia cases, researchers have identified other mutations that cause a change in amino acids (the building blocks of proteins). In these cases, arginine is replaced by proline at position 696 in the IKAP protein's chain of amino acids (also written as Arg696Pro), or proline is replaced by leucine at position 914 (also written as Pro914Leu). Together, these mutations cause the resulting IKAP protein to malfunction.[13]

As an autosomal recessive disorder, two mutated alleles of the IKBKAP gene are required for the disorder to manifest. However, despite the predominance of the same single-base mutation being the reputed cause of familial dysautonomia, the severity of the affected phenotype varies within and between families.[3]

Kinetin (6-furfurylaminopurine) has been found to have the capacity to repair the splicing defect and increase wild-type IKBKAP mRNA expression in vivo. Further research is still required to assess the fitness of kinetin as a possible future oral treatment.[14]

See also

edit

References

edit
  1. ^ a b c Holmberg C, Katz S, Lerdrup M, Herdegen T, Jäättelä M, Aronheim A, Kallunki T (2002). "A novel specific role for I kappa B kinase complex-associated protein in cytosolic stress signaling". The Journal of Biological Chemistry. 277 (35): 31918–28. doi:10.1074/jbc.M200719200. PMID 12058026.
  2. ^ Mezey E, Parmalee A, Szalayova I, Gill SP, Cuajungco MP, Leyne M, Slaugenhaupt SA, Brownstein MJ (September 2003). "Of splice and men: what does the distribution of IKAP mRNA in the rat tell us about the pathogenesis of familial dysautonomia?". Brain Research. 983 (1–2): 209–14. doi:10.1016/s0006-8993(03)03090-7. PMID 12914982. S2CID 24160053.
  3. ^ a b c d e f g Slaugenhaupt SA, Blumenfeld A, Gill SP, Leyne M, Mull J, Cuajungco MP, Liebert CB, Chadwick B, Idelson M, Reznik L, Robbins C, Makalowska I, Brownstein M, Krappmann D, Scheidereit C, Maayan C, Axelrod FB, Gusella JF (2001). "Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia". American Journal of Human Genetics. 68 (3): 598–605. doi:10.1086/318810. PMC 1274473. PMID 11179008.
  4. ^ a b Close P, Creppe C, Cornez I, Chariot MA, Chariot A (2007). "[Molecular and cellular characterization ion of IKAP protein and the Elongator complex. Implications for familial dysautonomia]". Bulletin et Mémoires de l'Académie Royale de Médecine de Belgique. 162 (5–6): 315–22. PMID 18405001.
  5. ^ Rahl PB, Chen CZ, Collins RN (March 2005). "Elp1p, the yeast homolog of the FD disease syndrome protein, negatively regulates exocytosis independently of transcriptional elongation". Molecular Cell. 17 (6): 841–53. doi:10.1016/j.molcel.2005.02.018. PMID 15780940.
  6. ^ Cuajungco MP, Leyne M, Mull J, Gill SP, Gusella JF, Slaugenhaupt SA (September 2001). "Cloning, characterization, and genomic structure of the mouse Ikbkap gene". DNA and Cell Biology. 20 (9): 579–86. doi:10.1089/104454901317094990. PMID 11747609.
  7. ^ Cohen L, Henzel WJ, Baeuerle PA (September 1998). "IKAP is a scaffold protein of the IkappaB kinase complex". Nature. 395 (6699): 292–6. Bibcode:1998Natur.395..292C. doi:10.1038/26254. PMID 9751059. S2CID 4327300.
  8. ^ Krappmann D, Hatada EN, Tegethoff S, Li J, Klippel A, Giese K, Baeuerle PA, Scheidereit C (September 2000). "The I kappa B kinase (IKK) complex is tripartite and contains IKK gamma but not IKAP as a regular component". The Journal of Biological Chemistry. 275 (38): 29779–87. doi:10.1074/jbc.M003902200. PMID 10893415.
  9. ^ Hawkes NA, Otero G, Winkler GS, Marshall N, Dahmus ME, Krappmann D, Scheidereit C, Thomas CL, Schiavo G, Erdjument-Bromage H, Tempst P, Svejstrup JQ (January 2002). "Purification and characterization of the human elongator complex". The Journal of Biological Chemistry. 277 (4): 3047–52. doi:10.1074/jbc.M110445200. PMID 11714725.
  10. ^ Xu H, Lin Z, Li F, Diao W, Dong C, Zhou H, Xie X, Wang Z, Shen Y, Long J (August 2015). "Dimerization of elongator protein 1 is essential for Elongator complex assembly". Proceedings of the National Academy of Sciences of the United States of America. 112 (34): 10697–702. Bibcode:2015PNAS..11210697X. doi:10.1073/pnas.1502597112. PMC 4553795. PMID 26261306.
  11. ^ Close P, Hawkes N, Cornez I, Creppe C, Lambert CA, Rogister B, Siebenlist U, Merville MP, Slaugenhaupt SA, Bours V, Svejstrup JQ, Chariot A (May 2006). "Transcription impairment and cell migration defects in elongator-depleted cells: implication for familial dysautonomia". Molecular Cell. 22 (4): 521–31. doi:10.1016/j.molcel.2006.04.017. hdl:2268/2904. PMID 16713582.
  12. ^ Huang B, Johansson MJ, Byström AS (April 2005). "An early step in wobble uridine tRNA modification requires the Elongator complex". RNA. 11 (4): 424–36. doi:10.1261/rna.7247705. PMC 1370732. PMID 15769872.
  13. ^ Anderson SL, Coli R, Daly IW, Kichula EA, Rork MJ, Volpi SA, Ekstein J, Rubin BY (March 2001). "Familial dysautonomia is caused by mutations of the IKAP gene". American Journal of Human Genetics. 68 (3): 753–8. doi:10.1086/318808. PMC 1274486. PMID 11179021.
  14. ^ Axelrod FB, Liebes L, Gold-Von Simson G, Mendoza S, Mull J, Leyne M, Norcliffe-Kaufmann L, Kaufmann H, Slaugenhaupt SA (November 2011). "Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia". Pediatric Research. 70 (5): 480–3. doi:10.1203/PDR.0b013e31822e1825. PMC 3189334. PMID 21775922.

Further reading

edit

  This article incorporates public domain material from Genetics Home Reference. United States National Library of Medicine.


edit


Retrieved from "https://en.wikipedia.org/w/index.php?title=IKBKAP&oldid=1237067447"